UBS initiates coverage on 6 pharma stocks. Sun Pharma, Cipla among top buys

The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both 'Buy' and 'Sell' ratings on a range of pharmaceutical stocks.

featured-image

Pharma Bets Sun Pharma | CMP: Rs 1,949 Cipla | CMP: Rs 1,671 Lupin | CMP: Rs 2,221 Zydus Life | CMP: Rs 1,074 Dr Reddy's Labs | CMP: Rs 6,755 Aurobindo Pharma | CMP: Rs 1,510.